Identification of Entacapone as a Novel β-Arrestin 1 Biased Antagonist of CXCR7
Open Access
Abstract
Background: The C-X-C chemokine receptor type 7 (CXCR7), also known as atypical chemokine receptor 3 (ACKR3), primarily signals through β-arrestin and plays a pivotal role in tumor progression, inflammation, and neurodegenerative diseases. CXCR7 antagonists block chemokine binding and dampen β-arrestin signaling. Accordingly, identification of such antagonists is highly desirable for therapeutic development against CXCR7 driven pathologies. Methods: Through microscale thermophoresis (MST) screening of a Food and Drug Administration (FDA)-approved drug library, entacapone was identified as a CXCR7 binder. The NanoBit complementation assay was employed to evaluate the effect of entacapone on CXCR7 mediated β-arrestin 1/2 recruitment. Molecular docking was performed to predict the binding pocket and binding sites. Results: Entacapone specifically bound to CXCR7 with a Kd value of 6.04 µM. Although entacapone did not directly activate CXCR7, it selectively inhibited CXCL12 and VUF11207 induced β-arrestin 1 recruitment with no significant effect on β-arrestin 2 recruitment. Molecular docking suggested that entacapone interacted with key residues via hydrophobic contacts, including Trp100, Phe124, Gln301, and Leu305, and formed hydrogen bonds with Ser103, Asn108, and Tyr51 in the transmembrane core, collectively suggesting a possible binding mode compatible with stabilizing the receptor in an inactive conformation. Conclusions: Entacapone, a clinically well established COMT inhibitor, is reported for the first time as a novel biased antagonist of CXCR7, providing a new candidate molecule for drug repurposing.Keywords
Funding Information
- Chengdu University of Traditional Chinese Medicine (030040043)
- Natural Science Foundation of Sichuan Province (2025NSFJQ0032)
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine (CBCM2024107)
- Sichuan Provincial Administration of Traditional Chinese Medicine Special Fund
This publication has 36 references indexed in Scilit:
- Inhibition of constitutive activity of the atypical chemokine receptor 3 by the small-molecule inverse agonist VUF16840Molecular Pharmacology, 2025
- ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating EffectsNeurochemical Research, 2024
- The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson’s Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years OnNeurology and Therapy, 2024
- Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239Journal of Medicinal Chemistry, 2020
- Pharmacogenomics of GPCR Drug TargetsCell, 2018
- MicroScale Thermophoresis: Interaction analysis and beyondJournal of Molecular Structure, 2014
- Tau-Derived-Hexapeptide 306VQIVYK311 Aggregation Inhibitors: Nitrocatechol Moiety as A Pharmacophore In Drug DesignACS Chemical Neuroscience, 2013
- Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonistsEuropean Journal of Medicinal Chemistry, 2012
- Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patientsAnnals of Neurology, 1997
- Federal Regulation I-Food and Drug AdministrationJournal of the American Pharmaceutical Association (Practical Pharmacy ed.), 1947